Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 5 6 7 8 9 … 48 Next »

Otezla effectiveness, safety, and drug survival study

Threaded Mode
Otezla effectiveness, safety, and drug survival study
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 55,030
Threads: 3,481
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 2
PQOLS: 2
Treatment: Ilumetri / Coconut Oil
#1
News  Fri-10-04-2020, 12:27 PM
This study evaluated the effectiveness, safety, and drug survival of Otezla (apremilast) at 52 weeks in patients with moderate to severe plaque psoriasis or palmoplantar psoriasis in routine clinical practice.

Quote:
Background:
Little has been published on the real‐world effectiveness and safety of apremilast in psoriasis.

Objectives:
To evaluate the effectiveness, safety, and drug survival of apremilast at 52 weeks in patients with moderate to severe plaque psoriasis or palmoplantar psoriasis in routine clinical practice.

Methods:
Retrospective, multicenter study of adult patients with moderate to severe plaque psoriasis or palmoplantar psoriasis treated with apremilast from March 2016 to March 2018.

Results:
We studied 292 patients with plaque psoriasis and 85 patients with palmoplantar psoriasis. The mean (SD) Psoriasis Area and Severity Index (PASI) score was 10.7 (7.0) at baseline and 3.0 (4.2) at 52 weeks. After 12 months of treatment, 73.6% of patients had a PASI score of 3 or less. In terms of relative improvement by week 52, 49.7% of patients achieved PASI‐75 (≥ 75% reduction in PASI score) and 26.5% achieved PASI‐90. The mean physician global assessment score for palmoplantar psoriasis fell from 4.2 (5.2) at baseline to 1.3 (1.3) at week 52. Overall drug survival after 1 year of treatment with apremilast was 54.9 %. The main reasons for treatment discontinuation were loss of efficacy (23.9%) and adverse events (15.9%). Almost half of the patients in our series (47%) experienced at least one adverse event. The most common events were gastrointestinal problems.

Conclusions:
Apremilast may be a suitable alternative for the treatment of moderate to severe psoriasis and palmoplantar psoriasis. Although the drug has a good safety profile, adverse gastrointestinal effects are common.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Otezla
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Tremfya super response study Fred 4 416 Thu-04-08-2022, 19:34 PM
Last Post: mataribot
News Effectiveness of (IL)-17A to other biologics in patients with psoriasis Fred 3 624 Fri-01-07-2022, 11:57 AM
Last Post: Fred
News One year Tremfya evaluation of efficacy & safety Fred 1 543 Fri-03-06-2022, 13:09 PM
Last Post: Forest Walker
News Long term efficacy and safety of Siliq / Kyntheum Fred 8 1,002 Tue-15-03-2022, 21:53 PM
Last Post: Caroline
News Sleep disturbance in psoriasis [Study] Fred 5 1,411 Mon-17-01-2022, 21:05 PM
Last Post: jiml



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2022 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB
Linear Mode
Threaded Mode